Physician profile
Marty N Bennett
NPI 1487616272
$1,844,258.69
in general payments reported to CMS, 2019-2025
33 companies · $398K in 2025
The $398K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120K · 2020: $114K · 2021: $166K · 2022: $323K · 2023: $361K · 2024: $363K · 2025: $398K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $731K · Consulting Fee: $146K · Travel and Lodging: $125K · Honoraria: $87K · Food and Beverage: $32K · Education: $12.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $731,212.00 |
| Consulting Fee | $146,471.50 |
| Travel and Lodging | $124,803.49 |
| Honoraria | $87,475.00 |
| Food and Beverage | $32,174.65 |
| Education | $12.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $566,100.95 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $517,573.05 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Allergan, INC. | $238,424.68 | 2019-2021 | |
| Axsome Therapeutics, INC. | $184,865.53 | 2022-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $139,937.47 | 2021-2025 | Lybalvi, Aristada |
| Vanda Pharmaceuticals INC. | $64,880.90 | 2019-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58,324.32 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $38,744.95 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Supernus Pharmaceuticals, INC. | $28,740.40 | 2022-2024 | Qelbree, Qelbree |
| Lundbeck LLC | $1,329.74 | 2019-2025 | Rexulti, Abilify Asimtufii, Brintellix |
| Neurocrine Biosciences, INC. | $1,207.70 | 2019-2025 | Ingrezza |
| Johnson & Johnson Health Care Systems INC. | $585.00 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $450.23 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Noven Therapeutics, LLC | $339.87 | 2023-2025 | Xelstrym, Secuado |
| Corium, LLC | $337.10 | 2023-2025 | Azstarys |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $316.66 | 2019-2024 | Trintellix |
| Ironshore Pharmaceuticals INC. | $306.38 | 2019-2024 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $293.10 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $292.78 | 2024-2025 | Cobenfy |
| Jazz Pharmaceuticals INC. | $180.28 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $176.76 | 2021-2022 | |
| Bausch Health US, LLC | $160.07 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $160.00 | 2023-2024 | Quviviq |
| Eisai INC. | $137.72 | 2020-2021 | |
| Tris Pharma INC | $99.32 | 2023 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $85.92 | 2019-2021 | |
| Almatica Pharma LLC | $64.05 | 2022-2023 | Loreev Xr |
| Neos Therapeutics, Lp | $54.92 | 2023-2024 | Adzenys Xr-Odt |
| Validus Pharmaceuticals LLC | $28.38 | 2025 | Raldesy, Equetro |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.88 | 2019 | |
| Merck Sharp & Dohme LLC | $20.54 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.10 | 2019 | |
| Janssen Biotech, INC. | $5.94 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marty Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.